Dipeptidyl-peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations.
Dipeptidyl-peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations.
复制标题
DOI：
10.1111/j.2040-1124.2012.00220.x
复制
发表时间：
2012-12-20
影响因子：
3.2
通讯作者：
Seino Y
中科院分区：
文献类型：
--
作者：
Senmaru T;Fukui M;Kobayashi K;Iwase H;Inada S;Okada H;Asano M;Yamazaki M;Hasegawa G;Nakamura N;Iwasaki M;Yabe D;Kurose T;Seino Y
目的/前言： 二十碳五烯酸(EPA)能刺激小鼠分泌胰升糖素样肽-1(GLP-1)。我们研究了二肽基肽酶 IV(DPP-4)抑制剂对2型 糖尿病患者的疗效与血清EPA浓度的关系。材料和方法：连续62例 2型糖尿病患者接受 -4抑制剂单独治疗或作为口服降糖药的附加治疗，测定其血清EPA浓度。观察期间维持口服降糖药的剂量。在用DPP-4抑制剂治疗24 周后，我们评估了Hb A1c较基线下降与血清EPA浓度、年龄、性别、体重指数、基线Hb A1c和降糖药物使用之间的关系。结果：经DPP-4抑制剂治疗后， 血红蛋白A1c由8.1 ± 1.1%降至7.2 ± 1.0%。Hb A1c的降低与体重指数(r = −0.396，P = 0.0013)、年龄(r = 0.275，P = 0.0032)、基线时的Hb A1c(r = 0.490，P <； 0.0001)和对数EPA(r = 0.285，P = 0.0246)相关。多元回归分析显示，体重指数(β = −0.419，P = 0.0002)、基线时的血红蛋白A1c(β = 0.579，P <； 0.0001)和对数EPA(β = 0.220，P = 0.0228)是血红蛋白A1c降低的独立决定因素。结论：EPADPP-4抑制剂对血清 浓度较高的 2型糖尿病患者是有效的。(《糖尿病投资》，DOI：10.1111/j.2040-1124.2012.00220.x，2012年)
Aims/Introduction: Eicosapentaenoic acid (EPA) stimulates glucagon‐like peptide‐1 (GLP‐1) secretion in mice. We investigated the relationship between serum EPA concentrations and the efficacy of dipeptidyl‐peptidase IV (DPP‐4) inhibitor in patients with type 2 diabetes. Materials and Methods: Serum EPA concentrations were measured in 62 consecutive patients with type 2 diabetes who were newly given DPP‐4 inhibitor as a monotherapy or as an add‐on therapy to oral hypoglycemic agents. The dosage of oral hypoglycemic agents was maintained during the observation period. After 24 weeks of treatment with DPP‐4 inhibitor, we evaluated the relationships between a decrease in hemoglobin A1c from baseline and serum EPA concentrations, as well as age, sex, body mass index (BMI), hemoglobin A1c at baseline and usage of antidiabetic concomitant drugs. Results: Hemoglobin A1c was significantly decreased from 8.1 ± 1.1% to 7.2 ± 1.0% by DPP‐4 inhibitor. A decrease in hemoglobin A1c correlated with BMI (r = −0.396, P = 0.0013), age (r = 0.275, P = 0.0032), hemoglobin A1c at baseline (r = 0.490, P < 0.0001) and log EPA (r = 0.285, P = 0.0246). Multiple regression analysis showed that BMI (β = −0.419, P = 0.0002), hemoglobin A1c at baseline (β = 0.579, P < 0.0001) and log EPA (β = 0.220, P = 0.0228) were independent determinants of decrease in hemoglobin A1c. Conclusions: DPP‐4 inhibitor is effective in patients with type 2 diabetes with high serum EPA concentrations. (J Diabetes Invest, doi: 10.1111/j.2040‐1124.2012.00220.x , 2012)
登录
查看更多内容
影响因子：
4.9
作者：
Näslund, E;Barkeling, B;Hellström, PM
通讯作者：
Hellström, PM
影响因子：
4.4
作者：
Yanagisawa, Naotake;Shimada, Kazunori;Daida, Hiroyuki
通讯作者：
Daida, Hiroyuki
影响因子：
5.8
作者：
Hermansen, K.;Kipnes, M.;Stein, P.
通讯作者：
Stein, P.
影响因子：
7.1
作者：
von Schacky, C
通讯作者：
von Schacky, C
影响因子：
3.2
作者：
Seino Y;Fukushima M;Yabe D
通讯作者：
Yabe D